{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:24:20Z","timestamp":1792628660868,"version":"4.5.0"},"reference-count":87,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Antibody-mediated rejection (AMR) is a leading cause of kidney graft failure. Complement activation is involved in the AMR process. Our aim is to provide the current understanding of the pathophysiology related to complement-mediated injury in AMR, to present the current evidence regarding complement blockade in AMR management, and to point out emerging therapies and future directions in this area. The complement system plays an important role in the onset and progression of AMR. There is a balance between complement-dependent and -independent mechanisms in the development of rejection lesions. Classic and leptin pathways are involved in this process. C4d positivity is no longer a mandatory feature for AMR diagnosis but remains an independent predictor of negative outcomes. The current evidence regarding AMR treatment is limited. Terminal and proximal complement blockade has gained recognition in clinical practice. Eculizumab and C1 inhibitors are effective in the treatment of AMR as adjuvant therapies to the standard of care. The availability of novel complement inhibitors will lead to more effective and tailored treatment strategies.<\/jats:p>","DOI":"10.3390\/jcm14082810","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T20:24:16Z","timestamp":1745180656000},"page":"2810","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Complement in Antibody-Mediated Rejection of the Kidney Graft: From Pathophysiology to Clinical Practice"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3574-4635","authenticated-orcid":false,"given":"Bogdan Marian","family":"Sorohan","sequence":"first","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Kidney Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorina","family":"Tacu","sequence":"additional","affiliation":[{"name":"Department of Kidney Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"G\u00eengu","sequence":"additional","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Kidney Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silviu","family":"Guler-Margaritis","sequence":"additional","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Kidney Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Obri\u0219c\u0103","sequence":"additional","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Daniela","family":"T\u0103n\u0103sescu","sequence":"additional","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Nephrology, Emergency University Hospital, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gener","family":"Ismail","sequence":"additional","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u0103t\u0103lin","family":"Baston","sequence":"additional","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Kidney Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/ajt.14702","article-title":"An Economic Assessment of Contemporary Kidney Transplant Practice","volume":"18","author":"Axelrod","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.kint.2016.10.040","article-title":"Differences in Pathologic Features and Graft Outcomes in Antibody-Mediated Rejection of Renal Allografts Due to Persistent\/Recurrent versus de Novo Donor-Specific Antibodies","volume":"91","author":"Haas","year":"2017","journal-title":"Kidney Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence","volume":"12","author":"Mengel","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_4","first-page":"660","article-title":"Renal Graft Survival According to Banff 2013 Classification in Indication Biopsies","volume":"36","author":"Gimeno","year":"2016","journal-title":"Nefrologia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1681\/ASN.2016070797","article-title":"Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients","volume":"28","author":"Aubert","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.molimm.2019.06.002","article-title":"The Role of Complement in Antibody Mediated Transplant Rejection","volume":"112","author":"Thurman","year":"2019","journal-title":"Mol. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100573","DOI":"10.1016\/j.trre.2020.100573","article-title":"Angiotensin II Type 1 Receptor Antibodies in Kidney Transplantation: An Evidence-Based Comprehensive Review","volume":"34","author":"Sorohan","year":"2020","journal-title":"Transplant. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Sorohan, B.M., Baston, C., Tacu, D., Buc\u0219a, C., Tincu, C., Vizireanu, P., Sinescu, I., and Constantinescu, I. (2022). Non-HLA Antibodies in Kidney Transplantation: Immunity and Genetic Insights. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071506"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gibson, B., Connelly, C., Moldakhmetova, S., and Sheerin, N.S. (2023). Complement Activation and Kidney Transplantation; a Complex Relationship. Immunobiology, 228.","DOI":"10.1016\/j.imbio.2023.152396"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12026-009-8136-3","article-title":"Mechanisms Involved in Antibody- and Complement-Mediated Allograft Rejection","volume":"47","author":"Wasowska","year":"2010","journal-title":"Immunol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended Treatment for Antibody-Mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial","volume":"17","author":"Kulkarni","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/ajt.13663","article-title":"C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study","volume":"16","author":"Viglietti","year":"2016","journal-title":"Am. J. Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41581-018-0071-x","article-title":"The Multifaceted Role of Complement in Kidney Transplantation","volume":"14","author":"Biglarnia","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Santarsiero, D., and Aiello, S. (2023). The Complement System in Kidney Transplantation. Cells, 12.","DOI":"10.3390\/cells12050791"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"F1174","DOI":"10.1152\/ajprenal.00670.2020","article-title":"Aberrant Activation of the Complement System in Renal Grafts Is Mediated by Cold Storage","volume":"320","author":"Lo","year":"2021","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Jager, N.M., Venema, L.H., Arykbaeva, A.S., Meter-Arkema, A.H., Ottens, P.J., van Kooten, C., Mollnes, T.E., Alwayn, I.P.J., Leuvenink, H.G.D., and Pischke, S.E. (2022). Complement Is Activated During Normothermic Machine Perfusion of Porcine and Human Discarded Kidneys. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.831371"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/TP.0000000000000500","article-title":"Hypoxia and Complement-and-Coagulation Pathways in the Deceased Organ Donor as the Major Target for Intervention to Improve Renal Allograft Outcome","volume":"99","author":"Damman","year":"2015","journal-title":"Transplantation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.molimm.2016.11.004","article-title":"Complement-Mediated Inflammation and Injury in Brain Dead Organ Donors","volume":"84","author":"Poppelaars","year":"2017","journal-title":"Mol. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.transproceed.2018.02.157","article-title":"Functional Activity of the Complement System in Deceased Donors in Relation to Kidney Allograft Outcome","volume":"50","author":"Bartoszek","year":"2018","journal-title":"Transplant. Proc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5500\/wjt.v5.i2.52","article-title":"Update on Ischemia-Reperfusion Injury in Kidney Transplantation: Pathogenesis and Treatment","volume":"5","author":"Salvadori","year":"2015","journal-title":"World J. Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1111\/ajt.13797","article-title":"Targeting Complement Pathways During Cold Ischemia and Reperfusion Prevents Delayed Graft Function","volume":"16","author":"Yu","year":"2016","journal-title":"Am. J. Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2215\/CJN.15590920","article-title":"Chronic Allograft Injury","volume":"16","author":"Langewisch","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ki.1991.240","article-title":"Histopathologic Findings Associated with a Chronic, Progressive Decline in Renal Allograft Function","volume":"40","author":"Kasiske","year":"1991","journal-title":"Kidney Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1681\/ASN.2017050544","article-title":"Collectin-11 Promotes the Development of Renal Tubulointerstitial Fibrosis","volume":"29","author":"Wu","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"F1293","DOI":"10.1152\/ajprenal.00357.2019","article-title":"Complement C1r Serine Protease Contributes to Kidney Fibrosis","volume":"317","author":"Xavier","year":"2019","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.kint.2019.01.039","article-title":"The C5a\/C5aR1 Axis Promotes Progression of Renal Tubulointerstitial Fibrosis in a Mouse Model of Renal Ischemia\/Reperfusion Injury","volume":"96","author":"Peng","year":"2019","journal-title":"Kidney Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1111\/bph.15408","article-title":"Role of Intracellular Complement Activation in Kidney Fibrosis","volume":"178","author":"Portilla","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","first-page":"163","article-title":"BK-Virus Nephropathy and Simultaneous C4d Positive Staining in Renal Allografts","volume":"41","author":"Boucek","year":"2005","journal-title":"Cesk. Patol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/TP.0000000000004297","article-title":"Infection, Rejection, and the Connection","volume":"107","author":"Higdon","year":"2023","journal-title":"Transplantation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e1302","DOI":"10.1093\/cid\/ciaa1189","article-title":"Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the \u201cNet State of Immunosuppression\u201d","volume":"73","author":"Roberts","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1111\/j.1600-6143.2009.02819.x","article-title":"Effect of Antibodies on Endothelium: Minireview","volume":"9","author":"Zhang","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2215\/CJN.00700117","article-title":"Donor-Specific Antibodies in Kidney Transplant Recipients","volume":"13","author":"Zhang","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrneph.2012.61","article-title":"Pathology: Diagnostic Challenges in Chronic Antibody-Mediated Rejection","volume":"8","author":"Farkash","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ajt.12589","article-title":"Diagnosis and Management of Antibody-Mediated Rejection: Current Status and Novel Approaches","volume":"14","author":"Djamali","year":"2014","journal-title":"Am. J. Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1126\/science.271.5247.348","article-title":"C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity","volume":"271","author":"Dempsey","year":"1996","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.4049\/jimmunol.160.11.5273","article-title":"Expression of Complement Receptors 1 and 2 on Follicular Dendritic Cells Is Necessary for the Generation of a Strong Antigen-Specific IgG Response","volume":"160","author":"Fang","year":"1998","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.4049\/jimmunol.1000522","article-title":"Complement-Dependent Transport of Antigen into B Cell Follicles","volume":"185","author":"Gonzalez","year":"2010","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Vandendriessche, S., Cambier, S., Proost, P., and Marques, P.E. (2021). Complement Receptors and Their Role in Leukocyte Recruitment and Phagocytosis. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.624025"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/ki.2015.253","article-title":"The Emerging Role of Complement Inhibitors in Transplantation","volume":"88","author":"Legendre","year":"2015","journal-title":"Kidney Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"193724","DOI":"10.1155\/2012\/193724","article-title":"Antibody-Mediated Rejection in Kidney Transplantation: A Review","volume":"2012","author":"Puttarajappa","year":"2012","journal-title":"J. Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1097\/01.ASN.0000025780.03790.0F","article-title":"Capillary Deposition of Complement Split Product C4d in Renal Allografts Is Associated with Basement Membrane Injury in Peritubular and Glomerular Capillaries: A Contribution of Humoral Immunity to Chronic Allograft Rejection","volume":"13","author":"Regele","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): Updates on and Clarification of Criteria for T Cell\u2013 and Antibody-Mediated Rejection","volume":"20","author":"Loupy","year":"2020","journal-title":"Am. J. Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ajt.2023.10.016","article-title":"The Banff 2022 Kidney Meeting Report: Reappraisal of Microvascular Inflammation and the Role of Biopsy-Based Transcript Diagnostics","volume":"24","author":"Naesens","year":"2024","journal-title":"Am. J. Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2249.1991.tb02954.x","article-title":"Vascular Deposition of Complement-Split Products in Kidney Allografts with Cell-Mediated Rejection","volume":"86","author":"Feucht","year":"1991","journal-title":"Clin. Exp. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1681\/ASN.V10102208","article-title":"Complement Activation in Acute Humoral Renal Allograft Rejection: Diagnostic Significance of C4d Deposits in Peritubular Capillaries","volume":"10","author":"Collins","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ajt.14584","article-title":"Antibody-Mediated Rejection: New Approaches in Prevention and Management","volume":"18","author":"Montgomery","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1600-6143.2010.03364.x","article-title":"Significance of C4d Banff Scores in Early Protocol Biopsies of Kidney Transplant Recipients with Preformed Donor-Specific Antibodies (DSA)","volume":"11","author":"Loupy","year":"2011","journal-title":"Am. J. Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/ki.2011.497","article-title":"Pros and Cons for C4d as a Biomarker","volume":"81","author":"Cohen","year":"2012","journal-title":"Kidney Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/TP.0000000000002366","article-title":"A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology","volume":"102","author":"Roufosse","year":"2018","journal-title":"Transplantation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.5414\/CNP75271","article-title":"C4d-Negative Antibody-Mediated Rejection in Renal Allografts: Evidence for Its Existence and Effect on Graft Survival","volume":"75","author":"Haas","year":"2011","journal-title":"Clin. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/j.1600-6143.2009.02761.x","article-title":"Endothelial Gene Expression in Kidney Transplants with Alloantibody Indicates Antibody-Mediated Damage despite Lack of C4d Staining","volume":"9","author":"Sis","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/ajt.12079","article-title":"Molecular Diagnosis of Antibody-Mediated Rejection in Human Kidney Transplants","volume":"13","author":"Reeve","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/ctr.12689","article-title":"Multiplexed Color-Coded Probe-Based Gene Expression Assessment for Clinical Molecular Diagnostics in Formalin-Fixed Paraffin-Embedded Human Renal Allograft Tissue","volume":"30","author":"Adam","year":"2016","journal-title":"Clin. Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal Complement Inhibition Decreases Antibody-Mediated Rejection in Sensitized Renal Transplant Recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am. J. Transplant."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ajt.13168","article-title":"Positive Crossmatch Kidney Transplant Recipients Treated with Eculizumab: Outcomes beyond 1 Year","volume":"15","author":"Cornell","year":"2015","journal-title":"Am. J. Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/ajt.15175","article-title":"Long-Term Outcomes of Eculizumab-Treated Positive Crossmatch Recipients: Allograft Survival, Histologic Findings, and Natural History of the Donor-Specific Antibodies","volume":"19","author":"Schinstock","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1111\/ajt.15364","article-title":"Safety and Efficacy of Eculizumab in the Prevention of Antibody-Mediated Rejection in Living-Donor Kidney Transplant Recipients Requiring Desensitization Therapy: A Randomized Trial","volume":"19","author":"Marks","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The Use of Antibody to Complement Protein C5 for Salvage Treatment of Severe Antibody-Mediated Rejection","volume":"9","author":"Locke","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1542\/peds.2014-2275","article-title":"Eculizumab to Treat Antibody-Mediated Rejection in a 7-Year-Old Kidney Transplant Recipient","volume":"135","author":"Chehade","year":"2015","journal-title":"Pediatrics"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.transproceed.2015.06.029","article-title":"Eculizumab for Treatment of Refractory Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience","volume":"47","author":"Yelken","year":"2015","journal-title":"Transplant. Proc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.transproceed.2016.03.028","article-title":"Dosing Eculizumab for Antibody-Mediated Rejection in Kidney Transplantation: A Case Report","volume":"48","author":"Smith","year":"2016","journal-title":"Transplant. Proc."},{"key":"ref_63","first-page":"3197042","article-title":"Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation","volume":"2017","author":"Lanfranco","year":"2017","journal-title":"Case Rep. Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1097\/TP.0000000000002639","article-title":"Use of Eculizumab for Active Antibody-Mediated Rejection That Occurs Early Post-Kidney Transplantation: A Consecutive Series of 15 Cases","volume":"103","author":"Tan","year":"2019","journal-title":"Transplantation"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.6002\/ect.PediatricSymp2022.O15","article-title":"Use of Eculizumab in Pediatric Patients with Late Antibody-Mediated Rejection After Kidney Transplantation","volume":"20","author":"Siddiqui","year":"2022","journal-title":"Exp. Clin. Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.transproceed.2022.08.008","article-title":"Lack of Efficacy and Safety of Eculizumab for Treatment of Antibody-Mediated Rejection Following Renal Transplantation","volume":"54","author":"Heo","year":"2022","journal-title":"Transplant. Proc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1111\/j.1432-2277.2011.01290.x","article-title":"Prompt Reversal of a Severe Complement Activation by Eculizumab in a Patient Undergoing Intentional ABO-Incompatible Pancreas and Kidney Transplantation","volume":"24","author":"Biglarnia","year":"2011","journal-title":"Transpl. Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.transproceed.2012.03.053","article-title":"Case Report: Eculizumab Rescue of Severe Accelerated Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplant","volume":"44","author":"Stewart","year":"2012","journal-title":"Transplant. Proc."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.transproceed.2012.09.038","article-title":"Eculizumab Treatment of Acute Antibody-Mediated Rejection in Renal Transplantation: Case Reports","volume":"44","author":"Bernal","year":"2012","journal-title":"Transplant. Proc."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1111\/j.1600-6143.2012.04124.x","article-title":"Antibody Mediated Rejection Associated with Complement Factor H-Related Protein 3\/1 Deficiency Successfully Treated with Eculizumab","volume":"12","author":"Noone","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.transproceed.2013.02.062","article-title":"Eculizumab for Salvage Treatment of Refractory Antibody-Mediated Rejection in Kidney Transplant Patients: Case Reports","volume":"45","author":"Kocak","year":"2013","journal-title":"Transplant. Proc."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/petr.12187","article-title":"Plasmapheresis-Resistant Acute Humoral Rejection Successfully Treated with Anti-C5 Antibody","volume":"18","author":"Ghirardo","year":"2014","journal-title":"Pediatr. Transplant."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/TP.0000000000000184","article-title":"Report of the Inefficacy of Eculizumab in Two Cases of Severe Antibody-Mediated Rejection of Renal Grafts","volume":"98","author":"Burbach","year":"2014","journal-title":"Transplantation"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/TP.0000000000000298","article-title":"Eculizumab and Splenectomy as Salvage Therapy for Severe Antibody-Mediated Rejection after HLA-Incompatible Kidney Transplantation","volume":"98","author":"Orandi","year":"2014","journal-title":"Transplantation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1111\/ajt.13871","article-title":"Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study","volume":"16","author":"Montgomery","year":"2016","journal-title":"Am. J. Transplant."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/ajt.14528","article-title":"Anti-C1s Monoclonal Antibody BIVV009 in Late Antibody-Mediated Kidney Allograft Rejection\u2014Results from a First-in-Patient Phase 1 Trial","volume":"18","author":"Eskandary","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1097\/TP.0000000000002717","article-title":"Update on C1 Esterase Inhibitor in Human Solid Organ Transplantation","volume":"103","author":"Berger","year":"2019","journal-title":"Transplantation"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/TP.0000000000000592","article-title":"A Phase I\/II Placebo-Controlled Trial of C1-Inhibitor for Prevention of Antibody-Mediated Rejection in HLA Sensitized Patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1097\/TP.0000000000001804","article-title":"Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial","volume":"101","author":"Jilma","year":"2017","journal-title":"Transplantation"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"10846","DOI":"10.3389\/ti.2022.10846","article-title":"First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome with Eculizumab to Ravulizumab in a Renal Transplant Patient","volume":"35","author":"Jehn","year":"2022","journal-title":"Transpl. Int."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e1289","DOI":"10.1097\/TXD.0000000000001289","article-title":"Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome","volume":"8","author":"Schmidt","year":"2022","journal-title":"Transplant. Direct"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1111\/ajt.15922","article-title":"Intravenous Immunoglobulin Significantly Reduces Exposure of Concomitantly Administered Anti-C5 Monoclonal Antibody Tesidolumab","volume":"20","author":"Jordan","year":"2020","journal-title":"Am. J. Transplant."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/SLA.0000000000004996","article-title":"Anti-C5 Antibody Tesidolumab Reduces Early Antibody-Mediated Rejection and Prolongs Survival in Renal Xenotransplantation","volume":"274","author":"Adams","year":"2021","journal-title":"Ann. Surg."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"II29","DOI":"10.1093\/ndt\/gfad079","article-title":"Complement Inhibitors for Kidney Disease","volume":"38","author":"Wooden","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1097\/TP.0000000000004207","article-title":"Novel Complement C5 Small-Interfering RNA Lipid Nanoparticle Prolongs Graft Survival in a Hypersensitized Rat Kidney Transplant Model","volume":"106","author":"Ishigooka","year":"2022","journal-title":"Transplantation"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1038\/s41467-021-25745-7","article-title":"C3 Complement Inhibition Prevents Antibody-Mediated Rejection and Prolongs Renal Allograft Survival in Sensitized Non-Human Primates","volume":"12","author":"Schmitz","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ekir.2024.09.030","article-title":"Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis","volume":"10","author":"Bomback","year":"2025","journal-title":"Kidney Int. Rep."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2810\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:17:33Z","timestamp":1760030253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":87,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14082810"],"URL":"https:\/\/doi.org\/10.3390\/jcm14082810","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]}}}